LAG3 binding peptides patent | Defense Tech Base

LAG3 binding peptides

This disclosure provides peptides which bind to LAG3, such as SAPWEPLHWPEDWWQGTGEW (SEQ ID NO:1), and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

Publication details

Recorded assignee: Leidos, Inc.
Publication number: US 11407829 B2
Publication type: Utility patent grant
Publication date: Aug 9, 2022
Filing date: May 21, 2020
CPC classes: A61K39/39, A61K38/16, C07K16/2803, A61K45/06, A61K38/04, C07K14/00, C07K7/08, C12N15/11, A61P25/28, A61K38/10, C07K14/70503, A61K39/3955, A61P35/00, A61K2039/55516, C12N2310/315, C12N2310/321
Inventors: Gutierrez; Gabriel M., Kotraiah; Vinayaka, Phares; Timothy W., Pannucci; James, Mansour; Marc

Party names reflect the published document. Current ownership and legal status can change.

View patent publication →